<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147858</url>
  </required_header>
  <id_info>
    <org_study_id>NYX-2925-2005</org_study_id>
    <nct_id>NCT04147858</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptinyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aptinyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of NYX-2925 versus placebo for the treatment of fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to assess the efficacy and
      safety of NYX-2925 in subjects with fibromyalgia.

      The study will be 15-18 weeks in duration, including a 1-4 week screening period (dependent
      upon duration of analgesic medication washout period), followed by a 14-week double-blind,
      randomized, placebo-controlled treatment period. Subjects eligible for study will receive
      either NYX-2925 or placebo during the treatment period. All subjects will receive placebo at
      some point during the treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization algorithm, randomization allocation, allocation to study drug or placebo, timing for primary endpoints.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the mean NRS score</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Change in the mean NRS score assessing average pain intensity in the past 24 hours from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Sleep Interference (DSIS) score</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Change from baseline in the mean Daily Sleep Interference (DSIS) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGI-C)</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Patient Global Impression of Change (PGI-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving ≥30% pain reduction</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Percentage of subjects achieving ≥30% pain reduction in the mean NRS average pain intensity from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire-Revised (FIQR) score</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Change from baseline in the Fibromyalgia Impact Questionnaire-Revised (FIQR) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Inventory of Subjective Cognitive Impairment (MISCI) score</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Change from baseline in the Multidimensional Inventory of Subjective Cognitive Impairment (MISCI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System - Firbomyalgia (PROMIS-FM)</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Change from baseline in the Patient Reported Outcomes Measurement Information System - Firbomyalgia (PROMIS-FM)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other Endpoints</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Adverse Events</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>NYX-2925 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NYX-2925 50 mg administered orally. At some point in the study, all subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NYX-2925 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NYX-2925 100 mg administered orally. At some point in the study, all subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NYX-2925</intervention_name>
    <description>NYX-2925 administered orally</description>
    <arm_group_label>NYX-2925 100 mg</arm_group_label>
    <arm_group_label>NYX-2925 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Institutional Review Board approved written informed consent and privacy language
             (Health Insurance Portability and Accountability Act (HIPAA)) authorization.

          2. Consent to being included in a research subject database.

          3. ≥18 and ≤75 years of age.

          4. Meets the 2016 American College of Rheumatology criteria for fibromyalgia

          5. Fibromyalgia was diagnosed &gt;1 year prior to Screening.

          6. Score of ≥4 and ≤9 on the 11-point NRS for average pain over the past 24 hours at
             Visit 1.

          7. Subject agrees to use only acetaminophen treatment as needed for breakthrough pain
             related to fibromyalgia.

          8. Subject agrees not to initiate or change any non-pharmacologic interventions during
             the study.

          9. Body mass index (BMI) ≤40 kg/m2.

         10. Calculated creatinine clearance is ≥60 mL/minute/1.73m2 (Cockcroft-Gault formula).

         11. Absence of impaired hepatic function.

        Inclusion Criteria: Randomization Daily pain scores and diary compliance will be
        transferred into the interactive response technology system, which will be used to assess
        the criteria for randomization. Subjects whose mean of the daily average pain intensity
        score during the preceding 7 (±1) days is within the protocol-defined algorithm and with
        adequate compliance with daily diary completion will be eligible for randomization.

        Exclusion Criteria:

          1. Lifetime history of any psychotic and/or bipolar disorder.

          2. Uncontrolled major depressive disorder or generalized anxiety disorder

          3. Pain that would confound or interfere with the assessment of the subject's
             fibromyalgia pain.

          4. Concurrent autoimmune, infectious, or inflammatory disease.

          5. An untreated endocrine disorder that may confound fibromyalgia assessments.

          6. History of severe renal impairment.

          7. Known history of significant cardiovascular condition.

          8. Resting heart rate &lt;45 bpm or &gt;95 bpm.

          9. History of Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple
             sclerosis, or a history of seizures, epilepsy, or stroke.

         10. Ongoing clinically significant infectious disease.

         11. Concomitant use of protocol specified prohibited medications.

         12. Sensitivity, allergy to, or concomitant use of, N-methyl-D-aspartate receptor ligands.

         13. Use of NMDAR-binding drugs within 30 days prior to dosing or during the study.

         14. Current or recent history of a substance use disorder.

         15. Positive urine drug screen or positive breathalyzer test for alcohol.

         16. Meets the criteria for suicidal intent, plan and/ or behavior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Richfield</city>
        <state>Minnesota</state>
        <zip>55423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

